These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23312676)

  • 1. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension.
    Manor I; Magen A; Keidar D; Rosen S; Tasker H; Cohen T; Richter Y; Zaaroor-Regev D; Manor Y; Weizman A
    Eur Psychiatry; 2013 Aug; 28(6):386-91. PubMed ID: 23312676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension.
    Manor I; Magen A; Keidar D; Rosen S; Tasker H; Cohen T; Richter Y; Zaaroor-Regev D; Manor Y; Weizman A
    Eur Psychiatry; 2012 Jul; 27(5):335-42. PubMed ID: 21807480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial.
    Rheims S; Herbillon V; Gaillard S; Mercier C; Villeuve N; Villéga F; Cances C; Castelnau P; Napuri S; de Saint-Martin A; Auvin S; Nguyen The Tich S; Berquin P; de Bellecize J; Milh M; Roy P; Arzimanoglou A; Bodennec J; Bezin L; Kassai B;
    Epilepsia Open; 2024 Apr; 9(2):582-591. PubMed ID: 38173190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension.
    Vakhapova V; Richter Y; Cohen T; Herzog Y; Korczyn AD
    BMC Neurol; 2011 Jun; 11():79. PubMed ID: 21711517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms.
    Cornu C; Mercier C; Ginhoux T; Masson S; Mouchet J; Nony P; Kassai B; Laudy V; Berquin P; Franc N; Le Heuzey MF; Desombre H; Revol O
    Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):377-384. PubMed ID: 28993963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial.
    Hirayama S; Terasawa K; Rabeler R; Hirayama T; Inoue T; Tatsumi Y; Purpura M; Jäger R
    J Hum Nutr Diet; 2014 Apr; 27 Suppl 2():284-91. PubMed ID: 23495677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder.
    Bos DJ; Oranje B; Veerhoek ES; Van Diepen RM; Weusten JM; Demmelmair H; Koletzko B; de Sain-van der Velden MG; Eilander A; Hoeksma M; Durston S
    Neuropsychopharmacology; 2015 Sep; 40(10):2298-306. PubMed ID: 25790022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial.
    Vakhapova V; Cohen T; Richter Y; Herzog Y; Korczyn AD
    Dement Geriatr Cogn Disord; 2010; 29(5):467-74. PubMed ID: 20523044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
    Swanson JM; Greenhill LL; Lopez FA; Sedillo A; Earl CQ; Jiang JG; Biederman J
    J Clin Psychiatry; 2006 Jan; 67(1):137-47. PubMed ID: 16426100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children.
    Carucci S; Romaniello R; Demuru G; Curatolo P; Grelloni C; Masi G; Liboni F; Mereu A; Contu P; Lamberti M; Gagliano A; Zuddas A
    Eur Arch Psychiatry Clin Neurosci; 2022 Dec; 272(8):1453-1467. PubMed ID: 35672606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Individual Family Psychoeducational Psychotherapy and Omega-3 Fatty Acids in Youth with Subsyndromal Bipolar Disorder.
    Fristad MA; Young AS; Vesco AT; Nader ES; Healy KZ; Gardner W; Wolfson HL; Arnold LE
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):764-74. PubMed ID: 26682997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Crippa A; Tesei A; Sangiorgio F; Salandi A; Trabattoni S; Grazioli S; Agostoni C; Molteni M; Nobile M
    Eur Child Adolesc Psychiatry; 2019 Apr; 28(4):571-583. PubMed ID: 30246216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.
    Kean JD; Sarris J; Scholey A; Silberstein R; Downey LA; Stough C
    Psychopharmacology (Berl); 2017 Feb; 234(3):403-420. PubMed ID: 27921139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M; Childress AC; Greenbaum M; Yu M; Yan B; Jaffee M; Robertson B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):19-28. PubMed ID: 28816509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
    Wigal TL; Newcorn JH; Handal N; Wigal SB; Mulligan I; Schmith V; Konofal E
    CNS Drugs; 2018 Mar; 32(3):289-301. PubMed ID: 29557078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.